Cargando…

Present and Future Perspective on PLK1 Inhibition in Cancer Treatment

Polo-like kinase 1 (PLK1) is the principle member of the well conserved serine/threonine kinase family. PLK1 has a key role in the progression of mitosis and recent evidence suggest its important involvement in regulating the G2/M checkpoint, in DNA damage and replication stress response, and in cel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chiappa, Michela, Petrella, Serena, Damia, Giovanna, Broggini, Massimo, Guffanti, Federica, Ricci, Francesca
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9201472/ https://www.ncbi.nlm.nih.gov/pubmed/35719948 http://dx.doi.org/10.3389/fonc.2022.903016

Ejemplares similares

Combination of paclitaxel, bevacizumab and MEK162 in second line treatment in platinum-relapsing patient derived ovarian cancer xenografts
por: Ricci, Francesca, et al.
Publicado: (2017)

Stable CDK12 Knock-Out Ovarian Cancer Cells Do Not Show Increased Sensitivity to Cisplatin and PARP Inhibitor Treatment
por: Chilà, Rosaria, et al.
Publicado: (2022)

Onvansertib and paclitaxel combined in platinum-resistant ovarian carcinomas
por: Affatato, Roberta, et al.
Publicado: (2022)

Combinations of ATR, Chk1 and Wee1 Inhibitors with Olaparib Are Active in Olaparib Resistant Brca1 Proficient and Deficient Murine Ovarian Cells
por: Chiappa, Michela, et al.
Publicado: (2022)

The sternum reconstruction: Present and future perspectives
por: Aramini, Beatrice, et al.
Publicado: (2022)

The 5′UTR variant of ERCC5 fails to influence outcomes in ovarian and lung cancer patients undergoing treatment with platinum-based drugs
por: Rulli, Eliana, et al.
Publicado: (2016)

Platinum Resistance in Ovarian Cancer: Role of DNA Repair
por: Damia, Giovanna, et al.
Publicado: (2019)

Lack of Efficacy: When Opioids Do Not Achieve Analgesia from the Beginning of Treatment in Cancer Patients
por: Corli, Oscar, et al.
Publicado: (2019)

Evaluation of safety and efficacy of tivantinib in the treatment of inoperable or recurrent non-small-cell lung cancer
por: Broggini, Massimo, et al.
Publicado: (2013)

Patient-derived ovarian cancer xenografts re-growing after a cisplatinum treatment are less responsive to a second drug re-challenge: a new experimental setting to study response to therapy
por: Ricci, Francesca, et al.
Publicado: (2016)

Spatial Separation of Plk1 Phosphorylation and Activity
por: Bruinsma, Wytse, et al.
Publicado: (2015)

Identification of PLK1 as a New Therapeutic Target in Mucinous Ovarian Carcinoma
por: Affatato, Roberta, et al.
Publicado: (2020)

Biomarker Landscape in Neuroendocrine Tumors With High-Grade Features: Current Knowledge and Future Perspective
por: Prisciandaro, Michele, et al.
Publicado: (2022)

Emerging Role of PARP Inhibitors in Metastatic Triple Negative Breast Cancer. Current Scenario and Future Perspectives
por: Barchiesi, Giacomo, et al.
Publicado: (2021)

Cross-Talk between AURKA and Plk1 in Mitotic Entry and Spindle Assembly
por: Asteriti, Italia Anna, et al.
Publicado: (2015)

SETD3 Methyltransferase Regulates PLK1 Expression to Promote In Situ Hepatic Carcinogenesis
por: Cheng, Meng, et al.
Publicado: (2022)

Telepharmacy Services: Present Status and Future Perspectives: A Review
por: Baldoni, Simone, et al.
Publicado: (2019)

Preclinical and Clinical Evidence of Lurbinectedin in Ovarian Cancer: Current Status and Future Perspectives
por: Musacchio, Lucia, et al.
Publicado: (2022)

A Perspective on Polo-Like Kinase-1 Inhibition for the Treatment of Rhabdomyosarcomas
por: Gatz, Susanne A., et al.
Publicado: (2019)

CAR-T Cells in the Treatment of Urologic Neoplasms: Present and Future
por: Zhang, Zhengchao, et al.
Publicado: (2022)

Multi-Chemotherapeutic Schedules Containing the pan-FGFR Inhibitor ARQ 087 are Safe and Show Antitumor Activity in Different Xenograft Models()
por: Chilà, Rosaria, et al.
Publicado: (2017)

PLK4 initiates crosstalk between cell cycle, cell proliferation and macrophages infiltration in gliomas
por: Zhang, Xiaoyang, et al.
Publicado: (2022)

Combination of the c-Met Inhibitor Tivantinib and Zoledronic Acid Prevents Tumor Bone Engraftment and Inhibits Progression of Established Bone Metastases in a Breast Xenograft Model
por: Previdi, Sara, et al.
Publicado: (2013)

Polo-Like Kinase 4’s Critical Role in Cancer Development and Strategies for Plk4-Targeted Therapy
por: Zhang, Xiaoyang, et al.
Publicado: (2021)

Radiation Treatment in Women with Ovarian Cancer: Past, Present, and Future
por: Fields, Emma C., et al.
Publicado: (2017)

Platinum sensitivity and DNA repair in a recently established panel of patient-derived ovarian carcinoma xenografts
por: Guffanti, Federica, et al.
Publicado: (2018)

Role of mTOR and VEGFR Inhibition in Prevention of Metastatic Tumor Growth in the Spine
por: Kratzsch, Tobias, et al.
Publicado: (2020)

Editorial: Patient-derived tumor models for drug development
por: Sabaawy, Hatim E., et al.
Publicado: (2023)

Impact of ERCC1, XPF and DNA Polymerase β Expression on Platinum Response in Patient-Derived Ovarian Cancer Xenografts
por: Guffanti, Federica, et al.
Publicado: (2020)

Immune Checkpoint Inhibition for Triple-Negative Breast Cancer: Current Landscape and Future Perspectives
por: Yi, Huimei, et al.
Publicado: (2021)

Applications of Circulating Tumor DNA in Immune Checkpoint Inhibition: Emerging Roles and Future Perspectives
por: Lu, Chang, et al.
Publicado: (2022)

Exploration of the Combination of PLK1 Inhibition with Immunotherapy in Cancer Treatment
por: Li, Mengyuan, et al.
Publicado: (2018)

Activity of Birinapant, a SMAC Mimetic Compound, Alone or in Combination in NSCLCs With Different Mutations
por: Colombo, Marika, et al.
Publicado: (2020)

Dihydroartemisinin Suppresses the Tumorigenesis and Cycle Progression of Colorectal Cancer by Targeting CDK1/CCNB1/PLK1 Signaling
por: Yi, You-Cai, et al.
Publicado: (2021)

In vivo efficacy assessment of the CDK4/6 inhibitor palbociclib and the PLK1 inhibitor volasertib in human chordoma xenografts
por: Passeri, Thibault, et al.
Publicado: (2022)

Manipulating microRNAs for the Treatment of Malignant Pleural Mesothelioma: Past, Present and Future
por: Reid, Glen, et al.
Publicado: (2020)

Treatment strategies for clear cell renal cell carcinoma: Past, present and future
por: Yang, Junwei, et al.
Publicado: (2023)

Targeting cyclin-dependent kinases in sarcoma treatment: Current perspectives and future directions
por: Merlini, Alessandra, et al.
Publicado: (2023)

Predictive modeling of gene expression regulation
por: Regondi, Chiara, et al.
Publicado: (2021)

Perspectives on the Treatment of Advanced Thyroid Cancer: Approved Therapies, Resistance Mechanisms, and Future Directions
por: Porter, Ashleigh, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_prbrc3iigrqt4p4ie9pnjgusts